- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06985121
- Original Trial
Scalp Care Efficacy Evaluation for Premium Scalp Revitalizing Essence
Evaluation of the Scalp Skin Care Effects of Premium Scalp Revitalizing Essence、Premium Scalp Revitalizing Essence 2、Premium Scalp Revitalizing Essence 3
Study Overview
Status
Detailed Description
This is a prospective, randomized, double-blinded, and placebo-controlled study to investigate the effects of Premium Scalp Revitalizing Essence on changes in the skin texture of human scalp skin.
Sixty healthy adults aged from 18 to 60 will be recruited and randomly assigned into five groups, with 12 individuals in each group. Group 1 uses Placebo (Base formula without caffeine and panthenol); Group 2 uses the Base formula (Control with caffeine and panthenol); Group 3 uses Base + IGF-1 & FGF-7; Group 4 uses Base + Centella asiatica extracellular vesicles; Group 5 uses Base + Centella Asiatica Exosome + IGF-1 & FGF-7. Before using the test product, all 60 participants undergo the first scalp skin texture test. After 14 days of using the test product, a second scalp skin texture test is conducted; after 28 days of use, a third test is performed; after 42 days of use, a fourth test is conducted; and after 56 days of use, a fifth test is carried out. The scalp skin texture tests include measurements of skin (1) sebum content, (2) overall hair loss, (3) hair density, (4) scalp condition, (5) hair length, and other parameters. The Sebumeter® SM815 probe of the MPA580 device and the ScalpX Intelligent Scalp Diagnostic System will be used to measure the parameters of the study.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Taichung, Taiwan, 433304
- Hungkuang University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Healthy adults of any gender from the age of 18 to 60 years (inclusive).
- Absence of chronic diseases, major illnesses, or allergies.
- Major illnesses include cancer, post-stroke disorders, paralysis, acute myocardial infarction, coro-nary artery bypass surgery, end-stage renal disease, and major organ transplant or hematopoietic stem cell transplant
Exclusion Criteria:
- Currently taking any medication or using any scalp care products
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Group 3: Base formula plus IGF-1 & FGF-7.
Base formula plus insulin growth factor 1 (IGF-1) and fibroblast growth factor-7 (FGF-7)
|
Base formula plus insulin growth factor 1 (IGF-1) and fibroblast growth factor-7 (FGF-7).
Applied 1mL evenly to the scalp once daily after hair wash for 56 consecutive days.
|
|
Experimental: Base formula plus Centella asiatica extracellular vesicles
|
Base formula plus Centella asiatica extracellular vesicles.
Applied 1mL evenly to the scalp once daily after hair wash for 56 consecutive days.
|
|
Experimental: Group 5: Base formula plus Centella asiatica extracellular vesicles, IGF-1 & FGF-7.
Base formula plus Centella asiatica extracellular vesicles, insulin growth factor-1 (IGF-1) and fibroblast growth factor-7 (FGF-7).
|
Base formula plus Centella asiatica extracellular vesicles, insulin growth factor-1 (IGF-1) and fibroblast growth factor-7 (FGF-7).
Applied 1mL evenly to the scalp once daily after hair wash for 56 consecutive days.
|
|
Experimental: Group 2: Base formula only
Base formula consisting of active ingredients caffeine and panthenol (vitamin B5).
|
Base formula consisting of active ingredients caffeine and panthenol.
Applied 1mL evenly to the scalp once daily after hair wash for 56 consecutive days.
|
|
Placebo Comparator: Group 1: Placebo control
Base formula without caffeine and panthenol
|
Placebo control (base formula without caffeine and panthenol).
Applied 1mL evenly to the scalp once daily after hair wash for 56 consecutive days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sebum Content
Time Frame: Assessment conducted every 14 days from Day 0 to Day 56 (including Day 0)
|
Assess oil levels on the scalp at standardized scalp sites (left, right, and vertex).
Measured with C+K Multi Probe Adaptor MPA580 system using the Sebumeter® SM815 probe based on the grease spot photometry method with the sebum measurement cassette tape.
The change in light transmission corresponds to the amount of sebum on the tape and is displayed on a scale from 0 to 350 units.
|
Assessment conducted every 14 days from Day 0 to Day 56 (including Day 0)
|
|
Hair length
Time Frame: Assessment conducted every 14 days from Day 0 to Day 56 (including Day 0)
|
Hair length (cm): Assessed with the ScalpX Intelligent Scalp Diagnostic System with digital microscopy at standardized scalp sites (left, right, and vertex).
|
Assessment conducted every 14 days from Day 0 to Day 56 (including Day 0)
|
|
Hair density
Time Frame: Assessment conducted every 14 days from Day 0 to Day 56 (including Day 0)
|
Hair density (number of hairs/cm-square): Assessed with the ScalpX Intelligent Scalp Diagnostic System with digital microscopy at standardized scalp sites (left, right, and vertex).
|
Assessment conducted every 14 days from Day 0 to Day 56 (including Day 0)
|
|
Hair thickness
Time Frame: Assessment conducted every 14 days from Day 0 to Day 56 (including Day 0)
|
Hair thickness (micrometers): Assessed with the ScalpX Intelligent Scalp Diagnostic System with digital microscopy at standardized scalp sites (left, right, and vertex).
|
Assessment conducted every 14 days from Day 0 to Day 56 (including Day 0)
|
|
Hair loss
Time Frame: Assessment conducted every 14 days from Day 0 to Day 56 (including Day 0)
|
Hair loss: Assessed by the standardized hair combing test by counting the number of hairs shed after the participants' hair was combed over a clean surface for 60 strokes.
|
Assessment conducted every 14 days from Day 0 to Day 56 (including Day 0)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathological Conditions, Anatomical
- Skin Diseases
- Hypotrichosis
- Hair Diseases
- Pathological Conditions, Signs and Symptoms
- Skin and Connective Tissue Diseases
- Alopecia
- Peptides
- Amino Acids, Peptides, and Proteins
- Proteins
- Substandard Drugs
- Pharmaceutical Preparations
- Biological Factors
- Blood Proteins
- Somatomedins
- Insulin-Like Peptides
- Intercellular Signaling Peptides and Proteins
- Counterfeit Drugs
- Insulin-Like Growth Factor I
Other Study ID Numbers
- 25-016-A
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hair Condition
-
Finzelberg GmbH & Co. KGEurofins; Eurofins Dermscan PharmascanRecruitingSkin Condition | Skin Aging | Hair ConditionPoland
-
Hungkuang UniversitySchweitzer Biotech CompanyActive, not recruitingAlopecia | Hair Condition | Hair Loss | Hair Thinning | Sebum Production | Scalp Health | Hair HealthTaiwan
-
Hungkuang UniversitySchweitzer Biotech CompanyCompletedSkin Condition | Skin Health | Eyelashes | Hair Health | Eyelash GrowthTaiwan
-
TCI Co., Ltd.RecruitingSkin Condition | Nails, Ingrown | Hair FragilityTaiwan
-
University of SheffieldCompletedBurns | Skin Condition | Visible Difference | Acceptance and Commitment Therapy | ACT | Hair Condition | CraniofacialUnited Kingdom
-
Candela CorporationActive, not recruitingScars | Acne | Wrinkle | Tattoo Removal | Skin Conditions | Hair Reduction | Benign Cutaneous Vascular LesionsUnited States, Israel
-
Dong-A PharmaceuticalGlobal Medical Research Center Co., Ltd.CompletedHair Damage | Hair Health | Hair StrengthSouth Korea
-
University of Milano BicoccaCompleted
-
Two Lines LLCCitruslabsCompletedHair Aging | Hair GrayingUnited States
-
Vanderbilt UniversityUniversity of California, IrvineCompletedCondition 1 - Educational Condition (Educational Book Group) | Condition 2 - Non-educational Condition (Non-educational Book Group) | Condition 3 - Control Condition (No-book Group)United States
Clinical Trials on Base formula plus IGF-1 and FGF-7
-
Hungkuang UniversitySchweitzer Biotech CompanyActive, not recruitingAlopecia | Hair Condition | Hair Loss | Hair Thinning | Sebum Production | Scalp Health | Hair HealthTaiwan
-
Advanced DermatologyCompletedSkin Aging | Photoaging of SkinUnited States
-
University of California, San FranciscoGenentech, Inc.Completed
-
University of Geneva, SwitzerlandUniversity of LausanneRecruitingPeriodontal Diseases | Pharmacokinetics | AntibioticsSwitzerland
-
National Cancer Institute (NCI)CompletedLung Carcinoid Tumor | Metastatic Digestive System Neuroendocrine Tumor G1 | Paraganglioma | Pancreatic Polypeptide Tumor | Pancreatic Glucagonoma | Pancreatic Insulinoma | Recurrent Merkel Cell Carcinoma | Somatostatin-Producing Neuroendocrine Tumor | Stage IV Merkel Cell Carcinoma | Recurrent Digestive... and other conditionsUnited States
-
Thomas Jefferson UniversityGenentech, Inc.Active, not recruitingRecurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Indolent Adult Non-Hodgkin Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Refractory Marginal Zone Lymphoma | Recurrent Indolent Adult Non-Hodgkin...United States
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityTerminatedPrimary Myelofibrosis | Anemia | Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic... and other conditionsUnited States
-
National Cancer Institute (NCI)NRG OncologyTerminatedStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Lung Non-Squamous Non-Small Cell CarcinomaUnited States
-
University of WashingtonRecruitingDiffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma | Grade 3b Follicular LymphomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)RecruitingNeuroblastoma | Ganglioneuroblastoma | Ganglioneuroblastoma, NodularUnited States, Canada, Puerto Rico